Sivik Global Healthcare’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sivik Global Healthcare’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-57,500	Closed	-$5.02M	–	40
2024 Q1	$5.02M	Buy	57,500 +2,500	+5%	+$224K	1.18%	28
2023 Q4	$5.3M	Buy	55,000 +5,000	+10%	+$442K	2.22%	25
2023 Q3	$4.42M	Hold	50,000	–	–	2.24%	26
2023 Q2	$4.33M	Hold	50,000	–	–	1.01%	32
2023 Q1	$4.86M	Sell	50,000 -10,000	-17%	-$1.04M	2.09%	25
2022 Q4	$6.21M	Buy	60,000 +5,000	+9%	+$469K	2.92%	14
2022 Q3	$4.66M	Buy	55,000 +7,500	+16%	+$668K	2.59%	21
2022 Q2	$3.94M	Buy	47,500 +7,500	+19%	+$597K	2.24%	22
2022 Q1	$3.08M	Hold	40,000	–	–	1.27%	38
2021 Q4	$3.53M	Sell	40,000 -25,000	-38%	-$2.06M	1.51%	31
2021 Q3	$5.02M	Buy	65,000 +10,000	+18%	+$789K	1.2%	32
2021 Q2	$4.59M	Sell	55,000 -5,000	-8%	-$396K	0.9%	32
2021 Q1	$4.53M	Sell	60,000 -20,000	-25%	-$1.63M	1.65%	31
2020 Q4	$7.01M	Buy	80,000 +15,000	+23%	+$1.19M	2.86%	15
2020 Q3	$4.95M	Sell	65,000 -155,000	-70%	-$15.7M	2.13%	27
2020 Q2	$8.13M	Sell	220,000 -15,000	-6%	-$1.49M	2.69%	15
2020 Q1	$8.39M	Buy	235,000 +155,000	+194%	+$13.4M	3.31%	9
2019 Q4	$6.76M	Buy	80,000 +35,000	+78%	+$2.64M	2.51%	17
2019 Q3	$3.03M	Buy	45,000 +10,000	+29%	+$770K	1.53%	35
2019 Q2	$3M	Sell	35,000 -10,000	-22%	-$855K	0.72%	44
2019 Q1	$4M	Sell	45,000 -10,000	-18%	-$927K	1.47%	32
2018 Q4	$4.68M	Hold	55,000	–	–	2.52%	16
2018 Q3	$5.33M	Sell	55,000 -10,000	-15%	-$998K	1.9%	23
2018 Q2	$6.12M	Buy	65,000 +45,000	+225%	+$3.94M	2.35%	15
2018 Q1	$1.62M	Sell	20,000 -55,000	-73%	-$4.72M	0.76%	56
2017 Q4	$6.69M	Hold	75,000	–	–	2.48%	9
2017 Q3	$6.98M	Sell	75,000 -10,000	-12%	-$884K	2.37%	17
2017 Q2	$7.72M	Buy	85,000 +30,000	+55%	+$2.73M	2.83%	6
2017 Q1	$4.83M	Sell	55,000 -5,000	-8%	-$445K	2.25%	17
2016 Q4	$4.97M	Sell	60,000 -10,000	-14%	-$860K	2.37%	18
2016 Q3	$6.48M	Buy	70,000 +30,000	+75%	+$2.82M	3.27%	10
2016 Q2	$3.11M	Sell	40,000 -20,000	-33%	-$1.7M	1.55%	34
2016 Q1	$4.95M	Buy	60,000 +32,114	+115%	+$2.61M	2.19%	18
2015 Q4	$2.92M	Sell	27,886 -7,114	-20%	-$743K	1.39%	33
2015 Q3	$3.69M	Buy	35,000 +10,000	+40%	+$1.34M	1.79%	23
2015 Q2	$3.42M	Sell	25,000 -10,000	-29%	-$1.24M	1.19%	31
2015 Q1	$4.36M	Buy	35,000 +5,200	+17%	+$551K	1.48%	29
2014 Q4	$2.69M	Buy	29,800 +9,800	+49%	+$815K	1.09%	46
2014 Q3	$1.44M	Buy	+20,000	New	+$1.31M	0.66%	57
2014 Q1	–	Sell	-12,000	Closed	-$844K	–	69
2013 Q4	$844K	Buy	+12,000	New	+$815K	0.6%	53

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Sivik Global Healthcare's BMRN Position: Q2 2024 in Review

Sivik Global Healthcare sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 57,500 shares — an estimated $5.02M sold.

Sivik Global Healthcare first reported a position in BMRN in Q4 2013 and held it in 40 quarters. The position peaked at $8.39M in Q1 2020. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Sivik Global Healthcare reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Sivik Global Healthcare sold 57,500 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $5.02M.
Sivik Global Healthcare first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 40 quarters.
Sivik Global Healthcare's BioMarin Pharmaceuticals position peaked at $8.39M in Q1 2020.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Sivik Global Healthcare's 13F filing for Q2 2024, filed 29 Jul 2024.